What is Fibromyalgia Phase III DS-5565 Clinical Trial?

Category: Others

false

NCT02234583 is an open-label trial study on the effects of Mirogabalin, DS-5565, in fibromyalgia patients.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
1
Mild
0
None
0

Commonly reported side effects and conditions associated with Fibromyalgia Phase III DS-5565 Clinical Trial

Side effect Patients
Blurry vision 1
Loss of balance 1
Weight gain 1

Why patients stopped taking Fibromyalgia Phase III DS-5565 Clinical Trial

Multiple reasons could be selected

Reason Patients
Course of treatment ended 1
See 1 patient who's stopped using Fibromyalgia Phase III DS-5565 Clinical Trial

Duration

Stopped using Fibromyalgia Phase III DS-5565 Clinical Trial

Duration Patients
6 months - 1 year 1
Adherence
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Last updated:
There are no evaluations for Fibromyalgia Phase III DS-5565 Clinical Trial.